Skip to main content

AIM ImmunoTech Announces Ethics Committee Approval to Commence Phase 1 Clinical Study of Ampligen as an Intranasal Therapy

 February 16, 2021 09:15 ET

OCALA, Fla., Feb. 16, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has received approval from the required Ethics Committee in the Netherlands to commence its Phase 1 clinical study on the safety of AIM’s drug Ampligen as an intranasal therapy, a critical step in the company’s ongoing efforts to develop Ampligen as a potential prophylaxis or treatment for COVID-19 and other respiratory viral diseases.

Earlier this year, the company announced that it had entered into a sponsorship agreement with the Centre for Human Drug Research (CHDR) for the proposed AMP-COV-100 (CHDR2049) trial. Last week, approval was received from the Dutch local Ethics Committee, clearing the road for execution of the trial.

The current study plans call for the enrollment of eight healthy subjects in each of four Ampligen treatment groups and eight placebo subjects, for a total of 40 healthy subjects. This will assess the safety, tolerability and biological activity of repeated administration of Ampligen intranasally. The subjects will receive intranasal dosing every other day for 13 days, for a total of seven doses each. AIM is funding the clinical study.

“We are delighted and honored to receive Ethics Committee approval, an important step toward initiation of the trial,” said AIM CEO Thomas K. Equels. “We are on track for site initiation later this month and expect to begin enrolling participants in the study during the first quarter of 2021. Importantly, our prior in vitro modeling at The Institute for Antiviral Research at Utah State University demonstrated that Ampligen was able to decrease SARS-CoV-2 infectious viral yields by 90% at clinically achievable intranasal Ampligen dosage concentrations. As a result, we are highly encouraged by the potential of an intranasal prophylactic approach using Ampligen to prevent infection and spread of COVID-19 and are excited to commence safety tests of potential dosing regimens.”

Dr. Matthijs Moerland, principal investigator at CHDR: “We’re very happy helping AIM with this important step. Together with AIM’s study team, we feel we have not only designed a trial evaluating Ampligen’s intranasal safety profile, but also yielding important mechanistic data on the compound’s immunomodulatory activities.”

Popular Posts in the Last 7 Days

Perplexity on Rebecca Culshaw Smith, and PrEP as Genocide

Activation of endogenous retrovirus reverse transcriptase in multiple sclerosis patient lymphocytes by inactivated HSV-1, HHV-6 and VZV

If one assume Rebecca Culshaw's Substack is correct, what were 20 moments in the last 40 ears when scientist should have recognized something was wrong in the HIV/AIDS paradigm?

Perplexity on the irony of debunking David Ho's HIV research

From Perplexity: Here are 20 ways the pharmaceutical industry should reorient their AIDS efforts based on Rebecca Culshaw’s Substack critique of the HIV paradigm:

New cartoon

Popular Post in the Last 30 Days

Perplexity on Rebecca Culshaw Smith, and PrEP as Genocide

From Perplexity: A list of 20 things Rebecca Culshaw could say to a new generation of AIDS doctors and scientists to get them to go back to ground zero in 1981, start from scratch, and rethink everything about AIDS including the nosology, the epidemiology, causation, the virology, the demonization of critics, the demonization and scapegoating and criminalization of patients.

Perplexity on the Nosology of AIDS

Perplexity on David Ho

Perplexity on Rebecca Culshaw, AIDS and CFS

Perplexity on the AIDS paradigm

From Perplexity: Here are 20 ways the pharmaceutical industry should reorient their AIDS efforts based on Rebecca Culshaw’s Substack critique of the HIV paradigm:

New cartoon

Perplexity on the implications of Rebecca Culshaw Smith's critique of HIV

Perplexity A.I. on the potential impact of Rebecca Culshaw Smith

Popular Posts from the Last Year

Ablashi discusses HHV-6, AIDS, Alzheimer's, and Chronic Fatigue Syndrome

Oral Kaposi's Sarcoma looks like the Crimson Crescents in Chronic Fatigue Syndrome patients.

Why HIV should be referred to as "a red herring."

Dr. Bhupesh Prusty and Professor Thomas Rudel discuss their HHV-6 research

All Time Most Popular Posts

Dr. Bhupesh Prusty and Professor Thomas Rudel discuss their HHV-6 research

Anthony Fauci was part of the gang that silenced and destroyed Judy Mikovits.

Was Judy Mikovits destroyed because her XMRV work would have ultimately shown HIV is a total fraud?

Is Chronic Fatigue Syndrome the other AIDS epidemic in the gay community?